title: Schisantherin A protects lipopolysaccharide-induced acute respiratory distress syndrome in mice through inhibiting NF-κB and MAPKs signaling pathways.
abstract: Acute respiratory distress syndrome (ARDS) is characterized by polymorphonuclear neutrophils (PMNs) adhesion, activation, sequestration and inflammatory damage to alveolar-capillary membrane. Schisantherin A, a dibenzocyclooctadiene lignan isolated from the fruit of Schisandra sphenanthera, has been reported to have anti-inflammatory properties. In the present study, we aimed to investigate the protective effects of schisantherin A on LPS-induced mouse ARDS. The pulmonary injury severity was evaluated 7 h after LPS administration and the protective effects of schisantherin A on LPS-induced mouse ARDS were assayed by enzyme-linked immunosorbent assay and Western blot. The results revealed that the wet/dry weight ratio, myeloperoxidase activity, and the number of total cells, neutrophils and macrophages in the bronchoalveolar lavage fluid (BALF) were significantly reduced by schisantherin A in a dose-dependent manner. Meanwhile, pretreatment with schisantherin A markedly ameliorated LPS-induced histopathologic changes and decreased the levels of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6) and interleukin-1β (IL-1β) in the BALF. In addition, the phosphorylation of nuclear transcription factor-kappaB (NF-κB) p65, inhibitory kappa B alpha (IκB-α), c-jun NH2-terminal kinase (JNK), extracellular signal-regulated kinase (ERK) and p38 induced by LPS were suppressed by schisantherin A. These findings indicated that schisantherin A exerted potent anti-inflammatory properties in LPS-induced mouse ARDS, possibly through blocking the activation of NF-KB and mitogen activated protein kinases (MAPKs) signaling pathways. Therefore, schisantherin A may be a potential agent for the prophylaxis of ARDS.
authors: Department of Clinical Veterinary Medicine, College of Veterinary Medicine, Jilin University, Changchun, Jilin Province, People's Republic of China.
authors: Ershun
authors: E
authors: Zhou
authors: Department of Clinical Veterinary Medicine, College of Veterinary Medicine, Jilin University, Changchun, Jilin Province, People's Republic of China.
authors: Yimeng
authors: Y
authors: Li
authors: Department of Clinical Veterinary Medicine, College of Veterinary Medicine, Jilin University, Changchun, Jilin Province, People's Republic of China.
authors: Zhengkai
authors: Z
authors: Wei
authors: Department of Clinical Veterinary Medicine, College of Veterinary Medicine, Jilin University, Changchun, Jilin Province, People's Republic of China.
authors: Yunhe
authors: Y
authors: Fu
authors: TongLe School, Nanshan ShenZhen, Guangdong Province, People's Republic of China.
authors: He
authors: H
authors: Lei
authors: Department of Clinical Veterinary Medicine, College of Veterinary Medicine, Jilin University, Changchun, Jilin Province, People's Republic of China.
authors: Naisheng
authors: N
authors: Zhang
authors: Department of Clinical Veterinary Medicine, College of Veterinary Medicine, Jilin University, Changchun, Jilin Province, People's Republic of China.
authors: Zhengtao
authors: Z
authors: Yang
authors: Department of Clinical Veterinary Medicine, College of Veterinary Medicine, Jilin University, Changchun, Jilin Province, People's Republic of China. Electronic address: zhouershun594926@163.com.
authors: Guanghong
authors: G
authors: Xie
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D034242:Cyclooctanes / Q000627:therapeutic use*; D016207:Cytokines / Q000378:metabolism; D004149:Dioxoles / Q000627:therapeutic use*; D005638:Fruit; D006801:Humans; D017705:Lignans / Q000627:therapeutic use*; D008070:Lipopolysaccharides / Q000276:immunology; D008168:Lung / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D016676:Macrophages, Alveolar / Q000187:drug effects* / Q000276:immunology; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D020929:Mitogen-Activated Protein Kinase Kinases / Q000378:metabolism; D016328:NF-kappa B / Q000378:metabolism; D009504:Neutrophils / Q000187:drug effects* / Q000276:immunology; D008517:Phytotherapy; D010936:Plant Extracts; D012128:Respiratory Distress Syndrome / Q000188:drug therapy* / Q000276:immunology; D032141:Schisandra / Q000276:immunology*; D015398:Signal Transduction / Q000187:drug effects
chemical_list: D000893:Anti-Inflammatory Agents; D034242:Cyclooctanes; D016207:Cytokines; D004149:Dioxoles; D017705:Lignans; D008070:Lipopolysaccharides; D016328:NF-kappa B; D010936:Plant Extracts; C034557:schizandrer A; D020929:Mitogen-Activated Protein Kinase Kinases
keywords: Acute lung injury (ARDS); Anti-inflammatory; Lipopolysaccharide (LPS); Mitogen activated protein kinases (MAPKs); Nuclear transcription factor-kappaB (NF-κB); Schisantherin A